VBWG
Slides

Results from ASCOT-BPLA: A nglo- S candinavian C ardiac O utcomes T rial-Blood Pressure Lowering Arm

ASCOT-BPLA compared two combination antihypertensive regimens in 19,257 hypertensive patients with 3 or more other CV risk factors.

Results favored a regimen based on a calcium channel blocker (with or without an ACE inhibitor) over one based on a beta-blocker (with or without a diuretic).




Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm

Download VBWG05-ASCOT%20.ppt (12 slides - 0.2MB)

Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm Rationale ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial ASCOT-BPLA: Study design ASCOT-BPLA: Trial profile ASCOT-BPLA: Treatment algorithm for BP targets ASCOT-BPLA: Reduction in primary outcome (nonfatal MI and fatal CHD) ASCOT-BPLA: Reduction in fatal and nonfatal strokeASCOT-BPLA: Additional reductions in group receiving the amlodipine-based regimen ASCOT-BPLA: Reductions in BP over time ASCOT-BPLA: Overall results ASCOT-BPLA: Summary

Click link to journal article:



antihypertensiveardiacArmASCOTBPLAcandinavianhypertensivengloregimensrialutcomes

Related at vwbg.org

ASCOT: New Insights on Aggressive Risk Factor Intervention to Prevent Major CV Events In Hypertensive Patients

Cardiovascular (CV) disease remains the leading cause of death in the United States, claiming more lives each year than the next four leading causes of death combined.

ASCOT-LLA: Extending benefits of statins to hypertensive patients

Hypertension and hypercholesterolemia frequently coexist and the interaction of these important risk factors increases cardiovascular risk considerably.

CAFE, an ASCOT substudy

View/Download individual slides (7 Slides)
More related